Skip to main content

11-15-2016 | Sodium-glucose cotransporter-2 inhibitors | Book chapter | Article

2. SGLT2 Inhibitors for Treating Diabetes

Authors: MD Gerard McKay, MD Rachel Livingstone

Publisher: Springer International Publishing


Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a novel therapeutic action compared with the many drugs available to the prescriber to treat type 2 diabetes. The pharmacological action of this drug class is in the kidneys, which play an important role in glucose homeostasis by filtering and reabsorbing glucose in the proximal tubules. On a daily basis, the kidney filters approximately 180 g of glucose. The majority of filtered plasma glucose (80–90 %) is reabsorbed in the early proximal tubule by the high capacity, low affinity SGLT2 [1]. The other 10–20 % is reabsorbed by the low capacity but high-affinity SGLT1 in the more distal portion of the proximal tubule (Fig. 2.1) [2]. This is achieved by cotransporting glucose with sodium via Na+/K+–adenosine triphosphatase pumps. SGLT2 is selectively expressed in the kidney, whereas SGLT1 is also expressed in the gastrointestinal tract where it has a role in the absorption of glucose and galactose [3]. In healthy individuals, virtually all glucose is reabsorbed and the urine is free from glucose.

Please log in to get access to this content